Recently, the top journal in the field of cell pathology, Cancer Cytology, published an article on the AI system of Ruiqian Technology - AICyte® Independent operation for large-scale clinical research on cervical cytology screening.
This study conducted a meta-analysis of 160000 sample data from four tertiary hospitals in China (67472 from the Third Affiliated Hospital of Zhengzhou University, 46060 from Peking University Shenzhen Hospital, 25667 from Shijiazhuang Obstetrics and Gynecology Hospital, and 24649 from Jinan Maternal and Child Health Hospital). The results showed that with a 50% negative rejection rate, AICyte® The competence to independently conduct cervical cytology screening has been evaluated.
The diagram shows the ROC curve: for a 50% rejection rate, i.e. at a false positive rate (FPR) of 0.50, draw a vertical line intersecting each ROC curve, and the y value at the intersection point corresponds to the corresponding sensitivity or specificity. The results showed that the sensitivities for HSIL, LSIL, ASC-H, AGC, and ASC-US slides were 100%, 99.69%, 98.52%, 92.93%, and 85.39%, respectively.
In a sample study of 160000 patients from four hospitals, when AICyte® When the negative rejection rate is set to 50%, there is no missed diagnosis of high-grade squamous intraepithelial lesions (HSIL).
By comparing and analyzing with historical diagnostic results, i.e. standard TBS report content, AICyte® was used separately; The negative coincidence rate of the interpretation result is 98.8%.
According to the recommended workflow for cervical cell testing in the study, AICyte® When the negative rejection rate is 50%, the slides judged as negative by the system algorithm will no longer require manual review, which can greatly reduce the workload of pathologists.
Comprehensive evaluation
AICyte® When used alone with a 50% negative rejection rate, high sensitivity and negative predictive value (NPV) were displayed, This fully demonstrates AICyte® Can serve as an effective tool for cervical cytology screening.
In addition, using AICyte® Another advantage of this is that it significantly reduces the traditional manual reading time from an average of 180 seconds per slide to an average of 22.3 seconds per slide, and enables digital archiving of slide images.
When setting a negative rejection rate of 50%, the AI algorithm will interpret the slides as negative, eliminating the need for manual secondary review and effectively reducing the expected workload by 50%. For countries and regions where there is a shortage of cell technicians or cell pathologists, or for pathological practices seeking to optimize workflow, it can be considered another "weapon" for cervical cytology screening.
Product Display
Top Issue | AIcyte® Assist Professor Zeng Xianxu's team from the Third Affiliated Hospital of Zhengzhou University to be featured in the Journal of Modern Pathology!
About Guoqian
Guoqian Medical Technology (Suzhou) Co., Ltd. is jointly invested and established by Dr. Zhang Xu and seven other national major talent engineering experts who have successfully innovated and started businesses in the fields of biomedical and medical devices, as well as shareholders in other fields.
Guoqian Medical is committed to investing in medical device innovation technology industry, entrepreneurial incubation, and precise empowerment. Guoqian Venture Capital Management (Suzhou) Co., Ltd., a wholly-owned subsidiary, is a venture capital firm specializing in early-stage equity investment in medical devices. Adhering to the business philosophy of "achieving others' dreams", Guoqian Venture Capital invests and aggregates industries through its managed equity investment funds, while Guoqian Medical creates an industrial ecosystem through incubation and empowerment. The two business platforms are highly coordinated, creating a high-end medical equipment industry cluster and ecosystem in Suzhou High tech Zone.